Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotrokinra in moderately to severely active Crohn's disease
NL-OMON58826Phase 3Not yet recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Icotrokinra with Placebo (2 arms). Primary endpoints: Clinical response at Week I-12, Clinical remission at Week I-12 and 3 more. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
icotrokinra
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON58826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58826.